Ovarian Cancer: From Mechanisms to Novel Target Therapies

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 1 January 2025 | Viewed by 284

Special Issue Editor

Department of Medical Research, Chi Mei Medical Center, Liouying Campus, Tainan 736, Taiwan
Interests: drug resistance; cancer metastasis; signaling transduction; anti-cancer drug development

Special Issue Information

Dear Colleagues,

Epithelial ovarian cancer (EOC) is the leading cause of gynecologic malignancy-related deaths worldwide. Despite advances in multidisciplinary treatment, the overall mortality has remained steady over the past thirty years. Most EOC patients are diagnosed at an advanced stage, and they eventually develop chemo-resistant relapsed disease despite surgery and combination chemotherapy. To date, the mechanism underlying chemo-resistance in ovarian cancer remains unclear. In addition, ovarian cancer falls under a heterogeneous group of malignancies that arise from various cell types, and the genetic mechanisms involved in chemo-resistance should be complex and differentially defined among different subtypes of ovarian cancer. Thus, to develop novel therapeutic strategies, it is crucial to define reliable predictive biomarkers for different subtypes and therapeutic resistance.

Dr. Yi-Hui Wu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epithelial ovarian cancer
  • relapsed disease
  • subtypes
  • therapeutic resistance
  • metastasis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop